Research programme: vitamin D signal amplifiers - OPKO Health
Alternative Names: CTA002; CTA012; CYP24 inhibitors - Cytochroma; QW-1624F2-2Latest Information Update: 23 Apr 2014
At a glance
- Originator Johns Hopkins University
- Developer Cytochroma
- Class Vitamin D analogues
- Mechanism of Action CYP24 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Osteoporosis; Psoriasis
Most Recent Events
- 23 Apr 2014 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 23 Apr 2014 Discontinued - Preclinical for Psoriasis in Canada (Topical)
- 04 Mar 2013 OPKO Health acquires Cytochroma